Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We have successfully completed a Phase 1 clinical trial in healthy volunteers and initiated a Phase 2 proof-of-concept trial (named TOPAZ) in patients with later-onset (Type 2 and Type 3) SMA in the second quarter of 2019. In addition, we initiated the DRAGON Phase 1 clinical trial for our second product candidate, SRK-181, a highly specific inhibitor of latent TGF?1 activation, in patients with locally advanced and metastatic solid tumors in the first quarter of 2020. We believe SRK-181 has the potential to render resistant solid tumors vulnerable to immune checkpoint inhibitors such as anti-PD1/PDL1 therapies and drive tumor regression through combination therapy.
Talk about Scholar Rock Holding below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis